Seer Files Patent Infringement Lawsuit Against Nanomics

Rhea-AI Summary

News Market Reaction – SEER

-2.75%

2 alerts

-2.75% Session close to close

+19.8% Peak Tracked

$99.86M Market Cap

0.1x Rel. Volume

In the May 13 session, SEER declined 2.75%, reflecting a moderate negative market reaction. Argus tracked a peak move of +19.8% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement centers on Seer’s decision to defend its nanoparticle protein enrichment technolog...

Analysis

This announcement centers on Seer’s decision to defend its nanoparticle protein enrichment technology through a patent infringement lawsuit, supported by an IP estate of more than 250 patents and applications, including 84 issued patents. The recent favorable Inter Partes Review outcome for U.S. Patent No. 11,435,360 underscores the company’s focus on legal reinforcement of its platform. Investors may track litigation milestones, additional IP decisions, and how these efforts interact with ongoing activist, governance, and commercial developments.

Key Figures

Issued patents worldwide: 84 issued patents Total patent portfolio: More than 250 patents and applications Key patent number: U.S. Patent No. 11,435,360 +1 more

4 metrics

Issued patents worldwide 84 issued patents Size of Seer’s global patent portfolio cited in lawsuit release

Total patent portfolio More than 250 patents and applications Overall intellectual property estate supporting Proteograph Product Suite

Key patent number U.S. Patent No. 11,435,360 Subject of Inter Partes Review upheld by Patent Trial and Appeal Board

Additional asserted patents U.S. Patent Nos. 11,630,112, 12,050,222, 12,228,566, 12,590,948 Patents asserted in infringement lawsuit against Nanomics

Historical Context

5 past events · Latest: May 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 04	CCO appointment	Positive	-3.9%	New Chief Commercial Officer hired to drive Proteograph Product Suite adoption.
Apr 29	Earnings call notice	Neutral	+3.7%	Announcement of date and time for Q1 2026 results webcast.
Apr 29	Activist proposal response	Negative	-2.6%	Radoff-JEC Group responds to Seer’s rejection of its acquisition proposal.
Apr 27	Board rejects proposal	Positive	-1.0%	Board unanimously rejects unsolicited offer viewed as materially undervaluing Seer.
Apr 24	Improved acquisition proposal	Positive	+1.6%	Radoff-JEC Group submits improved non-binding proposal to acquire Seer.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent governance and corporate events often saw modest negative reactions, with one notable divergence where a positive management hire coincided with a share price decline.

Recent Company History

Over the past month, Seer navigated activist pressure and strategic decisions around an unsolicited acquisition proposal at $2.25–$2.35 per share, which the Board ultimately rejected as undervaluing its proteomics platform. Governance activity continued with a new Chief Commercial Officer appointed on May 4, 2026. An earnings date announcement for Q1 2026 also featured. Against this backdrop of activism, leadership changes, and valuation debate, today’s patent infringement lawsuit adds a legal/IP dimension to the story.

Key Terms

patent infringement, intellectual property, inter partes review, patent trial and appeal board, +3 more

7 terms

patent infringement regulatory

"today announced that it has filed a patent infringement suit against Nanomics"

Patent infringement occurs when someone makes, uses, sells or imports a product or process that is covered by another party’s patent without permission — like copying a chef’s secret recipe and selling the dish without consent. For investors it matters because alleged infringement can trigger costly lawsuits, damage awards, sales bans or forced licensing, any of which can reduce revenue, increase expenses and hurt a company’s stock value.

intellectual property regulatory

"defends its pioneering Proteograph® Product Suite intellectual property (IP)"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

inter partes review regulatory

"Final Written Decision in an Inter Partes Review (IPR) of U.S. Patent No. 11,435,360"

An inter partes review is a formal proceeding at the U.S. Patent Office where a third party asks a panel to re-examine and possibly cancel all or part of an issued patent based on earlier public information. Investors care because the outcome can remove or uphold a company’s exclusive rights, directly affecting product exclusivity, potential revenue, legal exposure and the valuation of businesses that rely on that patent—like asking a neutral referee to re-check a key call in a game.

patent trial and appeal board regulatory

"the Patent Trial and Appeal Board's issued a Final Written Decision in an Inter Partes Review"

The Patent Trial and Appeal Board is an administrative body that reviews and decides challenges to the validity of issued patents and hears appeals of patent office decisions. For investors, its rulings can make or break a company’s exclusive rights to a product or technology—similar to a referee overturning a game-winning call—affecting future revenue, legal costs, and the value of related securities.

injunctive relief regulatory

"Seer is seeking all available remedies, including monetary damages and injunctive relief."

A court-ordered instruction requiring a person or company to do or stop doing a specific action to prevent harm or preserve a situation. For investors, injunctive relief can immediately alter a business’s operations, block sales or product use, or preserve assets—like a referee pausing play to prevent unfair advantage—so it can swiftly affect revenue, legal exposure and share value while longer legal battles continue.

proteomics medical

"solution for standardized, robust, deep unbiased proteomics"

Proteomics is the large-scale study of all the proteins produced by a cell, tissue or organism, like taking a full inventory and watching how the workforce and machines inside a factory behave. For investors, proteomics matters because it helps identify drug targets, disease indicators and responses to treatments—information that can speed development, reduce risk, guide partnerships and reveal new commercial opportunities in biotech and diagnostics.

nanoparticle medical

"intellectual property in the field of nanoparticle protein enrichment."

A nanoparticle is an extremely tiny particle—often a thousand times smaller than the width of a human hair—measured at the scale of billionths of a meter. They act like microscopic packets or building blocks used to carry drugs, enhance materials, or enable new sensors, and their unique size can change how a product works or how regulators view its safety. Investors watch nanoparticle use because it can drive product advantage, regulatory scrutiny, manufacturing cost changes, and market potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Seer defends its pioneering Proteograph^® Product Suite intellectual property (IP)

REDWOOD CITY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has filed a patent infringement suit against Nanomics Biotechnology Co., Ltd. The asserted patents, U.S. Patent Nos. 11,435,360, 11,630,112, 12,050,222, 12,228,566, and 12,590,948, protect Seer’s intellectual property in the field of nanoparticle protein enrichment. Brigham and Women’s Hospital is joining this lawsuit as well.

Seer has imagined and pioneered the first solution for standardized, robust, deep unbiased proteomics and has a large patent portfolio of more than 250 patent applications and issued patents, including 84 issued patents worldwide. A large portion of Seer’s patents defend IP integral to Seer’s Proteograph^® Product Suite. As recent evidence regarding the strength of our IP, on March 23, the Patent Trial and Appeal Board's issued a Final Written Decision in an Inter Partes Review (IPR) of U.S. Patent No. 11,435,360 upholding key commercially important claims in Seer’s nano- and micro-particle protein enrichment patent. This successful IPR outcome serves as an example of the strengths of our carefully constructed IP estate.

“Seer has consistently pushed the boundaries of science and technology to empower our customers. As the pioneer of automated, deep, unbiased proteomics, we have a robust and expanding portfolio of intellectual property that protects our innovations," said Omid Farokhzad, Chair and Chief Executive Officer of Seer. "Our proprietary engineered nanoparticle technology is core to our solutions, and our customers demand and deserve the gold standard in proteomics technology. We will not allow inferior imitations to dilute the extraordinary progress we have made in offering our customers robust solutions that can fuel novel biological insights. We filed this lawsuit because Seer's IP is the backbone of the entire field of protein enrichment for automated, deep, unbiased proteomics, and we will defend it with the full force of our conviction, our resources, and our resolve.”

Nanomics infringes the asserted patents by manufacturing, using, offering to sell, and selling its Proteonano kits and workstations, and inducing others to do the same. Seer is seeking all available remedies, including monetary damages and injunctive relief.  

About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision, and reproducibility previously unattainable. Seer’s Proteograph^® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to overcome the throughput and complexity limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s proprietary technology and products and any third-party infringement thereof. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:
Patrick Schmidt
pr@seer.bio

Investor Contact:
Marissa Bych
investor@seer.bio